sacituzumab govitecan
gilead sciences
['bcsm', 'mbc']
now dr on sacituzumab in hr+, her2- mbc who have developed resistance to endocrine therapy and/or cdk 4/6i - small but statistically significant improvement in sacituzumab vs chemo. and my small i mean only 1.5 mo in this heavily pretreated population #asco22 #bcsm 
(former) doctor, mother, woman LIVING with metastatic breast cancer. Grant reviewer. Conference goer. METAvivor board member. She/her. #NotDeadYet for 8 years